Skip to main content

Table 1 Patient characteristics in 2 groups

From: I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular hepatocellular carcinoma

  Combined treatment TACE alone P value
Patients number 32 32
Age (years) 62.7 ± 11.8 62.1 ± 13.3 0.895
Gender 1.000
 Male 26 26  
 Female 6 6  
HBsAg (+) 22 31 0.003
AFP (mg/ml) 0.281
 ≥ 400 24 20  
 < 400 8 12  
Diameter (cm) 5.5 ± 1.9 5.8 ± 2.7 0.627
Number of tumor 0.146
 Single 25 19  
 Multiple 7 12  
ECOG PS 0.091
 0 23 16  
 1 7 11  
 2 1 5  
BCLC stage 0.737
 A 16 14  
 B 12 15  
 C 4 3  
Child–Pugh class 0.756
 A 26 25  
 B 6 7  
Exophytic cases 11 7 0.266
PVTT 4 3 1.000
Extra-hepatic meatastasis 4 0 0.121
Target treatment 0.412
 Yes 8 11  
 No 24 21  
  1. ECOG PS Eastern Cooperative Oncology Group performance status, AFP Alphafetoprotein, BCLC Barcelona clinic liver cancer, PVTT portal vein tumor thrombi, TACE transcatheter arterial chemoembolization